(Q43620342)

25 November 2017

Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor (English)

1 reference

25 November 2017

0 references

1 reference

de Luis DA

1

1 reference

25 November 2017

Bachiller P

series ordinal

2

1 reference

25 November 2017

Aller R

series ordinal

3

1 reference

25 November 2017

language of work or name

1 reference

1 May 2001

1 reference

25 November 2017

1 reference

25 November 2017

17

1 reference

25 November 2017

5

1 reference

25 November 2017

414-415

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900582-2

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900582-2

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900582-2

7 January 2021

HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900582-2

7 January 2021

Structure and biochemical effects of fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900582-2

7 January 2021

Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900582-2

7 January 2021

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900582-2

7 January 2021

10.1016/S0899-9007(01)00582-2

Identifiers

DOI

1 reference

25 November 2017

1 reference